Our Team

• Dr Parmjot Bains MB ChB, M Phil (Cantab)

  Chief Executive Officer Perseis Therapeutics, MB ChB, M Phil (Cantab)

  Dr Bains is the Chief Executive Officer of Perseis Therapeutics. Previously, she was the co-Chief Executive Officer of Neuren Pharmaceuticals. Dr Bains trained as a medical doctor, before moving on to work in Australia as a management consultant for McKinsey and Company, a global management consultancy. Prior to Neuren, she worked in senior management positions at Fonterra Cooperative Group, New Zealand's largest company, within their biotechnology and specialty ingredients businesses. Dr Bains brings a strong commercial and medical background to Perseis.

• Professor Peter Lobie BMedSci, MB,BS (Hons), PhD, FRSNZ

  Chief Scientific Officer, BMedSci, MB,BS (Hons), PhD, FRSNZ

  Professor Peter Lobie is the inventor of the TFF and GH intellectual property that is being developed in Perseis, and is responsible for the overall science program in Perseis. Peter also heads the Liggins Institute's Molecular Endocrinology and Cancer Research group and is an international authority on molecular mechanisms of hormone action. In 2007, Professor Peter Lobie was appointed New Zealand's first Professor of Breast Cancer Research, funded by The Breast Cancer Research Trust. The purpose of the Chair is to build a team of researchers concentrating on research into breast cancer that may lead to treatments and prevention of the disease. In the past, Peter Lobie has worked at two of the world's most prestigious research centres: the Karolinska Institute in Stockholm, and the Institute of Molecular and Cell Biology in Singapore.

• Hilary Lewis B Com, MBA

  Board Member

  Hilary Lewis is the Chair for New Zealand of The Breast Cancer Research Trust. The goal of the Trust is to find a cure for Breast Cancer within the next decade. She is using her leadership, finance, IT and strategic management skills to achieving this goal. She brings these valuable skills and objectives to the Board of Perseis. Hilary is a qualified accountant,completed an MBA in 1994 and is a member of the NZ Institute of Directors. She is CEO - Australasia/CFO for Unimarket Ltd, a provider of e-procurement services. Previous to that she worked for House of Travel as e-commerce Director between 2004 and 2008, combining her passion for travel experiences with the online practicality of purchasing travel. She has also held a number of senior roles within finance and IT at Air New Zealand over 13 years.

• Tony Moffat

  Board Member

  Tony is the Acting CEO and Deputy Chair of The Breast Cancer Research Trust. Tony has a career of 25 years specialising in Sales, Marketing and General Management. He brings considerable experience, predominately from the travel and aviation industries and has lived and worked in markets across North Asia and most of Continental Europe. He has enjoyed senior Marketing, Regional and Group General Management roles with Air New Zealand, the House of Travel Group, and the Australian owned company, Stella Travel Services.

• Dr Robin Congreve, LLM, PhD

  Board Member

  Dr Congreve is the Chairman of the Neuren Board. He is a principal of Oceania & Eastern Group, a New Zealand private equity group which has provided private equity funding to both Neuren's predecessor companies, NeuronZ and EndocrinZ. Dr Congreve was founding Chairman of the Auckland Medical School Foundation which led to the formation of NeuronZ within the University of Auckland and subsequently to the introduction of private equity into that company and EndocrinZ. Dr Congreve was for many years a partner in Russell McVeagh specialising in taxation and business law. He was subsequently on the Boards of or chaired a number of public and private companies including NZ Railways Corporation, BNZ, Comalco NZ Limited, Lion Nathan Limited and TruTest Limited.

• Mr Larry Glass, BA (Biology)

  Board Member

  Mr Glass is the Chief Executive Officer of Neuren Pharmaceuticals and President US Operations. Mr Glass joined Neuren in early 2004 as the Executive Vice President, USA. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSE-listed company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson & Johnson.